Generate Biomedicines, Inc.

DUBLIN--( BUSINESS WIRE )--The "Digital Transformation and Emerging Technologies in the Healthcare Industry 2024 Edition" report has been added to ResearchAndMarkets.com's offering. The report examines the progress of digital transformation in the pharmaceutical industry. It assesses the industry's preparedness to embrace innovation, explores the challenges and opportunities associated with digital transformation as well as highlights current and emerging trends in technology-related investments. The pharmaceutical industry is facing ongoing shifts driven by declining profit margins, increasing cost pressures, and the need to both replenish pipelines and maximize peak sales, all while adhering to strict regulatory and legislative requirements. Although adopting innovative technologies is seen as a key strategy to mitigate these challenges, the digitalization process is complex, time-consuming, and requires significant investment, along with sustained commitment and transparent dialogue with various stakeholders, including employees, investors, and regulators. The pharmaceutical industry is experiencing steady advancement in digital transformation. Mirroring 2023 survey findings, operations enablement and innovation was selected as the main scope of digital transformation in 2024. Optimism regarding the growth of digital transformation in their organizations reached record highs among the pharma industry professionals. In line with previous years' results, lack of specific skills and talents was selected as the top hinderance for digital transformation. Digital privacy and data security issues have ranked as the top concern associated with digital transformation, closely followed by cybersecurity concerns. Strong leadership was regarded as the key driver for a successful digital transformation. Pharma industry professionals are prioritizing artificial intelligence (AI) for current and future investments. Digital transformation is a must for maintaining competitive advantage in the pharmaceutical industry. Scope Benchmark the level of business readiness and technology adoption. Gain a deeper understanding of the business functions affected the most by digital transformation. Identify and assess barriers to adopting emerging technologies. Define the critical requirements for success. Determine the importance of emerging technologies to the pharmaceutical industry. Evaluate current levels of investment and identity both present and future investment priorities. Analyze the impact of COVID-19, inflation, and other factors on digitalization efforts. Explore the impact of emerging technologies on the pharmaceutical value chain. Assess the role of digital transformation in sustaining competitive advantage. Reasons to Buy Stay up to date on the scope, challenges, and essentials for the digital transformation within the healthcare industry. Explore how innovations are transforming the healthcare industry and what impact on the sector these technologies will have in the near future. Develop and design your corporate strategies through an in-house expert analysis of the key factors of digital transformation and emerging technology in the healthcare sector. Develop business strategies by understanding the key factors of digital transformation and emerging technology in the healthcare sector. Identify emerging industry trends in the uptake of emerging technologies to gain a competitive advantage. Key Topics Covered: Study Design Key Findings Overview of Digital Transformation Digital Transformation Strategies Digital Transformation Objectives Obstacles to Digital Transformation Concerns Associated with Digital Transformation Necessities for Digital Transformation Emerging Technologies - Investment Trends Artificial Intelligence Case Studies Summary of Key Findings Appendix Competitive Landscape Amgen AB BenevolentAI Ltd Biolexis Therapeutics Inc Cellix Biosciences Inc Eli Lilly and Co Generate Biomedicines Inc Google Cloud Platform Hackensack Meridian Health Inc Healx Ltd Highmark Health InSilico Medicine Mount Sinai Health System Novartis AG Recursion Pharmaceuticals Inc For more information about this report visit https://www.researchandmarkets.com/r/r3umsv About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Flagship Pioneering has appointed two new CEO-partners to advise its portfolio companies and help steer its spinouts Apriori Bio and Valo Health, the life sciences incubator and investor told Endpoints News . Vaccine upstart Apriori Bio promoted its president Craig Williams to CEO, and computational-driven Valo Health named former Foundation Medicine CEO Brian Alexander as its new leader, Flagship told Endpoints on Wednesday. Endpoints reported in September that Valo’s interim CEO Graeme Bell had departed. Alexander joins Valo at a pivotal moment. The Boston-area startup expects a Phase 2 readout in diabetic retinopathy by year’s end, a spokesperson told Endpoints in September. Valo is testing OPL-0401, an oral small molecule that inhibits Rho kinase, or ROCK, 1 and 2. The biotech withdrew a different mid-stage drug last year. Alexander started at Valo on Wednesday after joining from Roche, where he was head of the Boston Roche Innovation Center and before that was CEO of Foundation Medicine, the Swiss pharma’s genomic profiling unit. Valo also promoted Brett Blackman, its business and innovation chief, to chief operating officer. At the same time, joining the board is Travis Wilson, a former Stealth BioTherapeutics CEO and now Flagship growth partner. The company launched in 2019 and was set for a $2.8 billion valuation had it followed through with a proposed combination with a special purpose acquisition company. That path to the public markets was nixed in November 2021 . The company later bought another startup, the cardiovascular drug discovery shop TARA Biosystems, and then inked a $60 million upfront and nearly $2.7 billion biobucks deal with Novo Nordisk in the cardiovascular space. Meanwhile, Williams started leading Apriori earlier this month as Flagship general partner Lovisa Afzelius focuses on other biotechs and projects at the incubator. Afzelius has been involved in multiple Flagship-founded startups, including Alltrna, Metaphore, and Generate:Biomedicines. Williams joined Flagship and Apriori last year after helping launch more than 15 vaccines and treatments during his prior roles at GSK. He also spent about three years leading the international unit of ViiV Healthcare, the HIV company owned by GSK, Pfizer and Shionogi, until the fall of 2021. Apriori unveiled $50 million in July 2022 to predict virus variants before new outbreaks occur and create vaccines for viral threats . Williams and Alexander are taking on the CEO-partner roles shortly after Flagship unveiled its $3.6 billion capital haul in July. The firm has also boosted its presence in Singapore , unveiled a few new startups and inked multiple pharma collaborations this year.

VICTORIA, British Columbia--( BUSINESS WIRE )-- ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, announces the details of its upcoming TECHDAY event on Friday, November 15, 2024, from 9:00 a.m. to 12:30 p.m. EST in Cambridge, Massachusetts. This exclusive gathering will highlight IPA’s latest advancements in AI-driven design, biologics innovation, and strategic technological developments. Highlights of TECHDAY: Presentation by Dr. Dirk Van Hyfte: Dr. Van Hyfte will present “Accelerating Drug Discovery with LENS ai : A Comprehensive Solution.” He will showcase LENS ai , BioStrand’s revolutionary platform, and discuss how it transforms drug discovery by integrating biotechnology, biotherapeutics, and artificial intelligence. Key topics include using HYFT® Universal Fingerprints to revolutionize multi-omics and data integration while accelerating drug discovery, development and optimization with AI-driven insights. LENS ai Demo: A live demonstration of the LENS ai platform, showcasing its capabilities in accelerating and enhancing the discovery and design of therapeutic antibodies through AI-driven insights. Presentation by Dr. Shuji Sato: Dr. Sato will present IPA’s B Cell Discovery Platform and discuss its integration with the company’s advanced AI and NGS workflows for highly efficient hit expansion. This process includes: Fast analysis of complete NGS repertoires Multimodal feature extraction that combines sequence, structure, and large language model (LLM) embeddings to deliver enhanced insights into sample diversity. Add-ons that complement outputs from phage display, B-cell, and hybridoma technologies, enabling the retrieval of antibody sequences with characteristics similar to known binders. Fireside Chat: Disruptive Dialogue: Empowering Drug Discovery Through Seamless Data Integration and AI-Powered Insights Participants: Dr. Dirk Van Hyfte , Head of Innovation and Co-founder, BioStrand (IPA) Jeff Fried , Director of Platform Strategy and Innovation, InterSystems This discussion will explore how vector search intelligence is at the core of the LENS ai platform, seamlessly integrated with the InterSystems IRIS data platform to deliver precise, scalable solutions that accelerate antibody discovery, enhance accuracy, and increase candidate diversity. AI-Driven Drug Discovery Summit USA 2024 Additionally, earlier that same week at the AI-Driven Drug Discovery Summit USA 2024, IPA will participate in another fireside chat titled Beyond conventional biologics: the intersection of machine learning and biological engineering to invent. Participants at the AI-Driven Drug Discovery Summit USA 2024: Adam Root , Vice President and Head of Protein Sciences, Generate Biomedicines Dr. Dirk Van Hyfte , Head of Innovation and Co-founder, BioStrand (IPA) The chat will focus on the integration of artificial intelligence and machine learning with wet lab infrastructure to accelerate biologics development. A recorded webcast of the TECHDAY presentations will be available in the Investors section of the IPA website under "Events and Presentations" at ir.ipatherapeutics.com . Interested in joining us for this exclusive TECHDAY experience? Space is limited - secure your spot by contacting Jennifer K. Zimmons, PhD, MBA, at Quantum Media: jen@quantum-corp.com About ImmunoPrecise Antibodies Ltd. ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the “IPA Family”). Forward-Looking Statements This press release contains forward-looking statements within the meaning of applicable United States securities laws and Canadian securities laws. Forward-looking statements are often identified by the use of words such as “expects” “estimates”, “intends”, “anticipates” or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements include, but are not limited to, statements regarding the capabilities, impact and results expected from BioStrand’s LENS ai platform. Although the Company believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks and uncertainties related to market and other conditions and the impact of general economic, industry or political conditions in the United States, Canada or internationally. You should also consult our quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties. These forward-looking statements speak only as of the date of this press release and the Company undertakes no obligation to revise or update any forward-looking statements for any reason, even if new information becomes available in the future. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Actual results could differ materially from those currently anticipated due to a number of factors and risks, as discussed in the Company’s Annual Report on Form 20-F for the year ended April 30, 2024 (which may be viewed on the Company’s SEDAR+ profile at www.sedarplus.ca and EDGAR profile at www.sec.gov/edgar ). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. Accordingly, readers should not place undue reliance on forward-looking statements contained in this news release. The forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. The Company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law.